Yikang Li, Bo Li, Xiao Xiao, Qiwei Qian, Rui Wang, Zhuwan Lyu, Ruiling Chen, NaNa Cui, Yiyan Ou, Xiting Pu, Qi Miao, Qixia Wang, Min Lian, M Eric Gershwin, Ruqi Tang, Xiong Ma, Zhengrui You
BACKGROUND AIMS: Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease characterized by infiltration of intrahepatic tissue-resident memory CD8+ T cells (TRM). Itaconate has demonstrated therapeutic potential in modulating inflammation. An unmet need for PSC is the reduction of biliary inflammation, and we hypothesized that itaconate may directly modulate pathogenic TRM. METHODS: The numbers of intrahepatic CD103+ TRM were evaluated by immunofluorescence in PSC (n = 32) and serum levels of itaconate in PSC (n = 64), primary biliary cholangitis (PBC) (n = 60), autoimmune hepatitis (AIH) (n = 49), and healthy controls (n = 109) were determined by LC-MS/MS...
July 26, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases